Domino Partners with Weiler Labeling Systems and Others to Provide Serialization Support

Domino North America and Weiler Labeling Systems (WLS) are teaming up to help pharmaceutical companies prepare for serialization, which is part of the Drug Quality and Security Act (DQSA) passed in November 2013. WLS designs and manufactures labeling equipment for a range of shapes and sizes of drug vials, bottles, syringes, and injector pens. Their labelers can integrate human-readable and/or 2-D Data Matrix code printers along with vision systems, sideserters, topserters, and more. Domino develops and manufactures coding and printing technologies. WLS’s President Ted Geiselman described Domino laser printing and WLS as “A match made in heaven.” A recent visit to the WLS assembly floor showed that Domino’s laser printers were featured on 19 labeling applications. A video by Weiler demonstrates the two technologies working together, showing how the partners address the challenges of serialization: “Domino is pleased to partner with pressure sensitive labeling solutions leader WLS, whose innovative commitment to the manufacturer experience continues to ensure they are the best supplier in both the Life Sciences and Food sectors," said Mark Shaffer, Pharmaceutical Business Development Manager for Domino North America, in a statement. "Working with their extensive portfolio and knowledge of maximum performance labeling solutions, Domino can easily provide effective serialization solutions required to support the new federal legislation requirements." At the upcoming Interphex (March 18-20) at the Javits Center in New York City, the Domino team will be at booth #2725 to answer questions and showcase latest product developments with partners WLS and Omega Designs, a provider of packaging solutions. Shaffer says that “after talking with several of our pharmaceutical customers, there is a strong consensus that this mandate will end questions about possible delays. Though this legislation will preempt the California e-Pedigree, it’s not a license to slow down compliance efforts and doing so would be a tremendous error in judgment.”
No votes yet